Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn
Gains access to OTX-201, a preclinical CAR T therapy being…
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
List view / Grid view
Gains access to OTX-201, a preclinical CAR T therapy being…
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
Bristol Myers Squibb has signed a worldwide capacity reservation and…
Bristol Myers Squibb has signed a worldwide capacity reservation and supply agreement with Cellares for CAR T-cell therapy manufacturing.
Bristol Myers Squibb has received approval from the US FDA…
Bristol Myers Squibb has received approval from the US FDA to begin commercial production at its newest cell therapy manufacturing site.
Securing in-house viral vector production capabilities in the US is…
Securing in-house viral vector production capabilities in the US is set to help Bristol Myers Squibb manufacture its two CAR T-cell therapies.